Wedbush initiated coverage on Impel NeuroPharma with a new price target
$IMPL
Biotechnology: Pharmaceutical Preparations
Health Care
Wedbush initiated coverage of Impel NeuroPharma with a rating of Outperform and set a new price target of $21.00
Save time and jump to the most important pieces.
Submission status for IMPEL NEUROPHARMA INC's drug TRUDHESA (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer
Submission status for IMPEL NEUROPHARMA INC's drug DIHYDROERGOTAMINE MESYLATE (ORIG-1) with active ingredient DIHYDROERGOTAMINE MESYLATE has changed to 'Approval' on 09/02/2021. Application Category: NDA, Application Number: 213436, Application Classification: Type 5 - New Formulation or New Manufacturer